| Characteristics | All (N = 44) | BCOR | | | |
|---|
| | | Negative (N = 23) | Focal weak +ve (N = 7) | Diffuse strong +ve (N = 14) | p-value |
|---|
| | No. (%) | No. (%) | No. (%) | No. (%) | |
|---|
| Age (years) |
| Mean ± SD | 56.84 ±7.93 | 62.52 ±4.98 | 51 ±7.85 | 50.42 ±4.23 | <0.001* |
| Median (Range) | 57 (39-72) | 62 (56-72) | 51 (39-60) | 50 (44-60) | |
| ≤ 55 years | 18 (40.9%) | 0 (0%) | 5 (27.8%) | 13 (72.2%) | <0.001‡ |
| > 55 years | 26 (59.1%) | 23 (88.5%) | 2 (7.7%) | 1 (3.8%) | |
| Histopathology |
| LMS | 22 (50%) | 19 (86.4%) | 2 (9.1%) | 1 (4.5%) | <0.001‡ |
| ESS | 22 (50%) | 4 (18.2%) | 5 (22.7%) | 13 (59.1%) | |
| Grade |
| Grade I | 9 (20.5%) | 9 (100%) | 0 (0%) | 0 (0%) | <0.001‡ |
| Grade II | 12 (27.3%) | 6 (50%) | 6 (50%) | 0 (0%) | |
| Grade III | 23 (52.3%) | 8 (34.8%) | 1 (4.3%) | 14 (60.9%) | |
| Extrauterine extension |
| Absent | 6 (13.6%) | 6 (100%) | 0 (0%) | 0 (0%) | 0.007‡ |
| Present | 9 (20.5%) | 7 (77.8%) | 2 (22.2%) | 0 (0%) | |
| N/A | 29 (65.9%) | 10 (34.5%) | 5 (17.2%) | 14 (48.3%) | |
| LVSI | | | | | |
| Absent | 21 (47.7%) | 15 (71.4%) | 5 (23.8%) | 1 (4.8%) | 0.001‡ |
| Present | 23 (52.3%) | 8 (34.8%) | 2 (8.7%) | 13 (56.5%) | |
| Other pelvic organ invasion |
| Absent | 15 (34.1%) | 9 (60%) | 5 (33.3%) | 1 (6.7%) | 0.010‡ |
| Present | 29 (65.9%) | 14 (48.3%) | 2 (6.9%) | 13 (44.8%) | |
| Adnexal invasion |
| Absent | 11 (25%) | 11 (100%) | 0 (0%) | 0 (0%) | 0.001‡ |
| Present | 33 (75%) | 12 (36.4%) | 7 (21.2%) | 14 (42.4%) | |
| Lymph node |
| Negative | 16 (36.4%) | 14 (87.5%) | 2 (12.5%) | 0 (0%) | 0.001‡ |
| Positive | 28 (63.6%) | 9 (32.1%) | 5 (17.9%) | 14 (50%) | |
| Distant metastasis |
| Absent | 29 (65.9%) | 19 (65.5%) | 7 (24.1%) | 3 (10.3%) | <0.001‡ |
| Present | 15 (34.1%) | 4 (26.7%) | 0 (0%) | 11 (73.3%) | |
| FIGO Stage |
| Stage I | 6 (13.6%) | 6 (100%) | 0 (0%) | 0 (0%) | <0.001‡ |
| Stage II | 10 (22.7%) | 8 (80%) | 2 (20%) | 0 (0%) | |
| Stage III | 13 (29.5%) | 5 (38.5%) | 5 (38.5%) | 3 (23.1%) | |
| Stage IV | 15 (34.1%) | 4 (26.7%) | 0 (0%) | 11 (73.3%) | |
| Stathmin |
| Negative | 19 (43.2%) | 4 (21.1%) | 5 (26.3%) | 10 (52.6%) | 0.007‡ |
| Focal weak +ve | 12 (27.3%) | 10 (83.3%) | 0 (0%) | 2 (16.7%) | |
| Diffuse strong +ve | 13 (29.5%) | 9 (69.2%) | 2 (15.4%) | 2 (15.4%) | |
| Transgelin |
| Negative | 25 (56.8%) | 7 (28%) | 5 (20%) | 13 (52%) | 0.004‡ |
| Focal weak +ve | 6 (13.6%) | 6 (100%) | 0 (0%) | 0 (0%) | |
| Diffuse strong +ve | 13 (29.5%) | 10 (76.9%) | 2 (15.4%) | 1 (7.7%) | |
| Cyclin-D1 |
| Negative | 24 (54.5%) | 21 (87.5%) | 2 (8.3%) | 1 (4.2%) | <0.001‡ |
| Focal weak +ve | 5 (11.4%) | 2 (40%) | 3 (60%) | 0 (0%) | |
| Diffuse strong +ve | 15 (34.1%) | 0 (0%) | 2 (13.3%) | 13 (86.7%) | |
- * Kruskal Wallis H test; ‡ Chi-square test; p < 0.05 is significant
